Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Scrip's Rough Guide To IDO

May 18 2017

• By Emily Hayes

depicting IDO mechanism of action — • Source: Bristol-Myers Squibb

Related Content

Flexus flips IDO inhibitors to Bristol-Myers for up to $1.25bn

Feb 24 2015

Incyte Eyes Big Phase III IDO Expansion, NewLink Plans First Pivotal Trial

May 04 2017

Bristol's CheckMate 067 Revives Debate On Rationing Yervoy/Opdivo Combo

Apr 04 2017

IDO Emerges As Clean Combo Partner, Rising Star At AACR

Apr 05 2017

NewLink-Genentech deal could be worth more than $1bn

Oct 21 2014

iTeos: Developing IO Therapeutics For Hot And Cold Tumors

Mar 15 2017

Immuno-Oncology's Next Wave: Key Targets And Emerging Players

Jun 02 2016

J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More

Jan 10 2017

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Roche Holding AG

Merck KGaA

Pfizer Inc.

AstraZeneca PLC

Incyte Corporation

Lumos Pharma, Inc.

Genentech, Inc.

Bristol Myers Squibb Company

iTeos Therapeutics Inc.

Additional Topics

ImmunoOncology Research & Development Clinical Trials Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window